Baricitinib for Graft-Versus-Host Disease Prophylaxis after HLA-matched Hematopoietic Cell Transplantation
Year: 2026
Type: preprint
Study design: Clinical Trial
Abstract: Acute graft-versus-host disease (aGVHD) is a leading cause of non-relapse mortality after allogeneic peripheral blood hematopoietic cell transplant (PB-HCT). The role of baricitinib, a balanced JAK1/2 inhibitor, for GvHD prophylaxis is unknown. Baricitinib after HLA-matched allogeneic PB-HCT was studied in a single-arm, open-label, phase I trial in 24 subjects. Subjects received baricitinib at 2 or 4 mg daily from days − 3 to + 100 post PB-HCT, followed by a taper. No primary graft failure, delayed engraftment or grade III/IV adverse events were observed. Overall incidence of grade III/IV aGVHD was 12.5% (3/24), of which 2/3 occurred after baricitinib discontinuation. Mild-moderate chronic GVHD occurred in 45.8% subjects, with no cases of severe chronic GVHD. Transplant-related mortality at day + 180 was 8% (2/24). The 1-year OS was 70% (95% CI 48–85%), PFS 62% (95% CI 40–78%), and refined GVHD and relapse free survival (GRFS) 33% (95% CI 15–52%). Correlative studies confirmed on-target effect of baricitinib resulting in downregulation of JAK1/2 pathways. Baricitinib is safe and tolerable after HLA-matched allogeneic PB-HCT with no episodes of primary graft failure and low rates of grade III/IV acute GVHD while on therapy.
Source: Research Square
Institutions: Washington University in St. Louis, MaineHealth
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: baricitinib, graft-versus-host disease prophylaxis, acute graft-versus-host disease, chronic graft-versus-host disease, allogeneic peripheral blood stem cell transplantation, HLA-matched transplantation, JAK1/2 inhibition, primary graft failure, non-relapse mortality, drug safety and tolerability
Open Access status: green
Funders: Foundation for Barnes-Jewish Hospital, Institute of Clinical and Translational Sciences, Gabrielle's Angel Foundation for Cancer Research, Alvin J. Siteman Cancer Center, Swim Across America, Incyte, Syndax Pharmaceuticals, Novo Nordisk, National Institutes of Health, National Cancer Institute, National Center for Advancing Translational Sciences
OpenAlex ID: W7225989868
